文献速递妇科

不止是拒绝治疗:一项美国国家癌症数据库分析——子宫内膜癌女性辅助治疗拒绝与种族生存差异

More than treatment refusal: a National Cancer Database analysis of adjuvant treatment refusal and racial survival disparities among women with endometrial cancer.
PubMed 文献 · Am J Obstet Gynecol · 2022-03-10

基于美国国家癌症数据库2004至2016年数据,纳入接受或拒绝辅助放疗或化疗的非西班牙裔黑人和白人子宫内膜癌患者,分析种族与治疗拒绝的关联及治疗拒绝对生存差异的中介效应。黑人女性更可能拒绝化疗(aOR 1.26,95%CI 1.15-1.37),但放疗拒绝无差异(aOR 1.00,95%CI 0.91-1.11);化疗拒绝可解释黑人女性3.2年生存差异中的1.9个月(4.9%),放疗拒绝未解释4.3年生存差异。

要点

  • 黑人女性拒绝化疗的调整比值比为1.26(95%CI 1.15-1.37),高于白人女性。
  • 放疗拒绝率在黑人女性和白人女性间无差异,调整比值比1.00(95%CI 0.91-1.11)。
  • 化疗拒绝仅解释黑人女性3.2年生存差异中的1.9个月(4.9%),放疗拒绝未解释4.3年生存差异。

核心结论

  • 黑人女性与白人女性在化疗拒绝上存在差异,该差异可能解释白人女性与黑人女性3.2年总生存差异中最多约2个月。
  • 放疗拒绝未解释推荐放疗女性中4.3年的生存差异。
  • 治疗拒绝最多只占子宫内膜癌生存种族差异的一小部分。
  • 作者认为,更好地理解患者拒绝治疗的原因及后续干预可能有助于改善部分女性的结局,但必须研究反映健康社会决定因素的其他差异原因。

研究设计与样本

  • 研究使用美国国家癌症数据库(基于医院的癌症登记数据库),识别2004年至2016年诊断为子宫内膜癌并接受或拒绝推荐放疗或化疗的非西班牙裔黑人和非西班牙裔白人女性。
  • 采用逻辑回归估计种族与治疗拒绝关联的多变量调整比值比和95%置信区间,并在种族特异性模型中检查治疗拒绝的预测因素。
  • 采用加速失效时间模型估计按种族的总生存绝对差异,并使用因果中介分析估计辅助治疗拒绝的种族差异对总生存种族差异的贡献比例。
  • 分析考虑总体研究人群及按组织学定义的分层,并调整社会人口学、肿瘤和机构特征。
  • 分析纳入75,447名被推荐放疗的子宫内膜癌患者和60,187名被推荐化疗的子宫内膜癌患者。

主要发现

  • 被推荐放疗的患者中6.4%拒绝治疗,被推荐化疗的患者中11.4%拒绝治疗。
  • 黑人女性中被推荐放疗者6.4%拒绝、被推荐化疗者9.6%拒绝;白人女性中被推荐放疗者6.4%拒绝、被推荐化疗者11.8%拒绝。
  • 调整社会人口学变量、机构特征和肿瘤特征后,黑人女性比白人女性更可能拒绝化疗(调整比值比1.26;95%置信区间1.15-1.37),放疗拒绝无差异(调整比值比1.00;95%置信区间0.91-1.11)。
  • 放疗拒绝的部分预测因素因种族而异,包括收入、教育、组织学、分期和化疗接受情况(交互作用P<.05),而化疗拒绝的预测因素在黑人和白人女性间总体相似。
  • 被推荐放疗的女性中,黑人女性平均生存时间比白人女性短4.3年,这似乎不能归因于放疗拒绝的差异;被推荐化疗的女性中,黑人女性平均生存时间比白人女性短3.2年,其中1.9个月(4.9%)可能归因于化疗拒绝的差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Disparities in adjuvant treatment between Black and White women with endometrial cancer exist and contribute to worse outcomes among Black women. However, factors leading to disparate treatment receipt are understudied. OBJECTIVE: We examined whether patient refusal of adjuvant treatment (chemotherapy or radiation) differed between Black and White women and whether treatment refusal mediated racial disparities in survival among women with endometrial cancer. STUDY DESIGN: We used the National Cancer Database, a hospital-based cancer registry, to identify non-Hispanic Black and non-Hispanic White women diagnosed with endometrial cancer from 2004 to 2016 who either received or refused recommended radiation or chemotherapy. We used logistic regression to estimate multivariable-adjusted odds ratios and 95% confidence intervals for associations between race and treatment refusal. We also examined predictors of treatment refusal in race-specific models. Accelerated failure time models were used to estimate absolute differences in overall survival by race. We used causal mediation analysis to estimate the proportion of racial differences in overall survival attributable to racial differences in adjuvant treatment refusal. We considered the overall study population and strata defined by histology, and adjusted for sociodemographic, tumor, and facility characteristics. RESULTS: Our analysis included 75,447 endometrial cancer patients recommended to receive radiation and 60,187 endometrial cancer patients recommended to receive chemotherapy, among which 6.4% and 11.4% refused treatment, respectively. Among Black women recommended for radiation or chemotherapy, 6.4% and 9.6% refused, respectively. Among White women recommended for radiation or chemotherapy, 6.4% and 11.8% refused, respectively. After adjusting for sociodemographic variables, facility characteristics, and tumor characteristics, Black women were more likely to refuse chemotherapy than White women (adjusted odds ratio, 1.26; 95% confidence interval, 1.15-1.37), but no difference in radiation refusal was observed (adjusted odds ratio, 1.00; 95% confidence interval, 0.91-1.11). Some predictors of radiation refusal varied by race, namely income, education, histology, stage, and chemotherapy receipt (P interactions<.05), whereas predictors of chemotherapy refusal were generally similar between Black and White women. Among women recommended for radiation, Black women survived an average of 4.3 years shorter than White women, which did not seem attributable to differences in radiation refusal. Among women recommended for chemotherapy, Black women survived an average of 3.2 years shorter than White women of which 1.9 months (4.9%) could potentially be attributed to differences in chemotherapy refusal. CONCLUSION: We observed differences in chemotherapy refusal by race, and those differences may be responsible for up to about 2 months of the overall 3.2-year survival disparity between White and Black women. Radiation refusal did not explain any of the 4.3-year disparity among women recommended for radiation. Treatment refusal accounts for, at most, a small fraction of the total racial disparity in endometrial cancer survival. Although a better understanding of the reasons for patient treatment refusal and subsequent intervention may help improve outcomes for some women, other causes of disparate outcomes, particularly those reflecting the social determinants of health, must be investigated.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Barrington DA, Sinnott JA, Nixon D, et al. More than treatment refusal: a National Cancer Database analysis of adjuvant treatment refusal and racial survival disparities among women with endometrial cancer. Am J Obstet Gynecol. 2022. PMID: 35283091. doi:10.1016/j.ajog.2022.03.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。